Stay updated on Adagrasib Combo in KRAS G12C Clinical Trial
Sign up to get notified when there's something new on the Adagrasib Combo in KRAS G12C Clinical Trial page.

Latest updates to the Adagrasib Combo in KRAS G12C Clinical Trial page
- Check4 days agoChange DetectedThe study record for the Phase 2/3 adagrasib and pembrolizumab trial in KRAS G12C-mutated non-small cell lung cancer is available, with its trial details and participation information. It also lists recruiting sites and contact details across numerous locations.SummaryDifference100%

- Check11 days agoChange DetectedThe ClinicalTrials.gov footer now shows revision v3.8.0 instead of v3.7.2. The study record remains inaccessible behind a 403 Forbidden message.SummaryDifference0.2%

- Check18 days agoNo Change Detected
- Check25 days agoChange DetectedA site-wide NIH announcement about the transition from “Artificial Intelligence” to “Super Intelligence” appears above the study record, and the displayed site revision changes from v3.7.1 to v3.7.2. The study record itself remains a 403 error page.SummaryDifference1%

- Check39 days agoChange DetectedThe footer now identifies the ClinicalTrials.gov site revision as v3.7.1 instead of v3.7.0. The page remains a 403 error page.SummaryDifference0.2%

- Check53 days agoChange Detected403 Forbidden error now appears on the page, replacing the expected study details with a generic error screen and a Home option. The study record is currently inaccessible on ClinicalTrials.gov.SummaryDifference21%

- Check60 days agoChange DetectedUpdated the label for locating contact information from 'Find Contact Information' to 'Find contact information' to align with the page's capitalization style. The release version was bumped from v3.6.6 to v3.7.0.SummaryDifference0.0%

Stay in the know with updates to Adagrasib Combo in KRAS G12C Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Adagrasib Combo in KRAS G12C Clinical Trial page.